SCHEMBL4875169

SCHEMBL4875169

COc1ccc(-c2ccc(Cl)cc2)c(-c2ccc3cc(-c4c(-c5ccccc5)c5sc(C(=O)O)cc5n4CC(=O)N4CCOCC4)ccc3n2)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 4/20 0.44
L3MBTL1 Q9Y468 1/20 0.41
ALDH1A1 P00352 3/20 0.38
MAPT P10636 1/20 0.38
ALOX15 P16050 1/20 0.38
PTGS2 P35354 2/20 0.36
GRIN2B Q13224 2/20 0.36
GRIN1 Q05586 1/20 0.36
EGFR P00533 1/20 0.36
TYMS P04818 1/20 0.36
LTA4H P09960 1/20 0.36
VDR P11473 1/20 0.36
SRC P12931 1/20 0.36
MAPK1 P28482 1/20 0.36
CTSK P43235 1/20 0.36
CREBBP Q92793 1/20 0.35
TDP1 Q9NUW8 2/20 0.35
TP53 P04637 2/20 0.35
KDM4E B2RXH2 2/20 0.35
HSD17B10 Q99714 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4865010 0.89 TDP1 (0.36) BRD4L3MBTL1ALDH1A1MAPTMAPK1
SCHEMBL4875162 0.88 BRD4 (0.43) BRD4L3MBTL1ALDH1A1MAPTALOX15
SCHEMBL4870899 0.86 ACHE (0.40) BRD4L3MBTL1ALDH1A1MAPTALOX15
SCHEMBL4868713 0.85 TDP1 (0.42) BRD4ALDH1A1MAPTPTGS2GRIN2B
SCHEMBL4868477 0.84 CCR2 (0.41) ALDH1A1MAPTMAPK1TP53KDM4E
SCHEMBL4877781 0.83 ACHE (0.43) BRD4L3MBTL1ALDH1A1MAPTALOX15
SCHEMBL4877524 0.83 GRIN2B (0.39) BRD4ALDH1A1PTGS2GRIN2BEGFR
SCHEMBL3928018 0.83 GRIN2B (0.42) BRD4ALDH1A1PTGS2GRIN2BEGFR
SCHEMBL4868467 0.83 KDM4E (0.44) L3MBTL1ALDH1A1MAPTPTGS2GRIN2B
SCHEMBL4876213 0.83 GRM5 (0.35) L3MBTL1ALDH1A1MAPTMAPK1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080051384-A1 ANTIVIRAL AGENTS GENELABS TECHNOLOGIES, INC. 2008-02-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080051384-A1 ANTIVIRAL AGENTS EIF2AK2, MAVS, ZC3HAV1 BRD4 3577/4885L3MBTL1 3239/4885ALDH1A1 1357/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.